logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Drugs

Results

Drugs

August 2021

Sabatolimab in addition to azacitidine for myelodysplastic syndromes – first-line

Sabatolimab in addition to azacitidine is in clinical development for the treatment of higher risk myelodysplastic syndromes (MDS) in adults. Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. MDS are long-term debilitating and life-threatening diseases Sabatolimab targets an inhibitory …

Drugs

August 2021

Pembrolizumab for Hepatocellular Carcinoma – Adjuvant

Pembrolizumab is in clinical development as an adjuvant treatment for hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer. This type of cancer develops from the main liver cells, called hepatocytes. Treatment and survival depends on the stage at which the cancer is diagnosed. HCC is more common in people who have …

Drugs

August 2021

Ravulizumab for treating generalised myasthenia gravis

Ravulizumab is currently in clinical development for the treatment of adults with generalised myasthenia gravis (gMG). gMG is a long-term autoimmune disorder where the body’s own immune system mistakenly attacks healthy cells in the neuromuscular junction (NMJ). The NMJ is a region where nerve cells transmit signals to muscle cells to result in muscle contraction. …

Drugs

August 2021

Pembrolizumab in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for early-strage breast cancer

Pembrolizumab in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy is in clinical development for the treatment of early-stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) breast cancer. Early breast cancer is where the disease is limited to the breast region and has not spread to other parts of the body. Treatment of …

Drugs

August 2021

Ruxolitinib cream for vitiligo

Ruxolitinib cream is in development for the treatment of vitiligo. Vitiligo is a common chronic skin condition where white patches develop on the skin, commonly on the hands and face. The condition is not life-threatening but can have an impact on self-esteem and wellbeing of sufferers. Risk factors include other autoimmune diseases and family history …

Drugs

August 2021

Ligelizumab for chronic spontaneous urticaria

Ligelizumab is in clinical development for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent patients. CSU is a skin condition characterised by raised and itchy rash (wheals) and/or angioedema that has lasted for more than six weeks, in the absence of an identified external cause (spontaneous) and in some cases up to …

Drugs

August 2021

Baricitinib for systemic lupus erythematosus

Baricitinib is in clinical development for adults with Systemic Lupus Erythematosus (SLE). SLE is an autoimmune disease where the body’s immune system attacks its own tissues and organs. Patients will often have periods where their symptoms flare-up and periods where their symptoms settle down. Mild SLE can cause joint problems and tiredness, whereas severe cases …

Drugs

August 2021

Infigratinib for unresectable locally advanced or metastatic cholangiocarinoma with FGFR2 rearrangements – second line

Cholangiocarcinoma (CCA) is a rare type of cancer that affects the bile ducts. Locally advanced CCA is when the cancer spreads from its original site to surround areas, but has not spread to other parts of the body. Metastatic CCA is when the cancer has spread to other areas of the body. Current treatment options …

Drugs

August 2021

Upadacitinib for ulcerative colitis

Upadacitinib is currently in clinical development for patients with ulcerative colitis (UC). UC is a long-term condition where parts of the large bowel become inflamed, causing urgent bloody diarrhoea and abdominal pain. The symptoms of UC often follow a pattern where individuals with the condition have periods of no symptoms or mild symptoms (remission) followed …

Drugs

August 2021

Mobocertinib for locally advanced or metastatic NSCLC

Mobocertinib (TAK-788) as a monotherapy is in clinical developmentfor the treatment oflocallyadvanced or metastatic non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK. In locally advanced or metastaticNSCLC(StageIIIB orIV),the cancer has spread beyond the lung which was initially affected. Symptoms of lung cancer include a persistent cough, shortness …

Get Alerts